Leniolisib Chemical Synthesis Patent Status
The chemical synthesis of leniolisib is protected by patents, which are crucial for its market exclusivity. Information on these patents can be found through resources like DrugPatentWatch.com [1].
When Does Leniolisib's Main Patent Expire?
The patent expiration timeline for leniolisib is a key consideration for potential generic competition. DrugPatentWatch.com tracks these dates, providing insights into when market exclusivity might end [1].
What Other Patents Protect Leniolisib?
Beyond the primary patent covering the compound itself, there may be additional patents related to leniolisib's manufacturing processes, specific formulations, or methods of use. These secondary patents can extend market protection even after the main compound patent expires. DrugPatentWatch.com is a resource for identifying such patents [1].
Who Owns the Patents for Leniolisib?
The ownership of leniolisib's patents typically lies with the company that developed and brought the drug to market. Identifying the patent holder is essential for understanding licensing agreements and potential future generic manufacturers.
How Are Drug Patents Challenged?
Pharmaceutical companies sometimes challenge existing drug patents. These challenges can be based on various grounds, such as prior art, obviousness, or insufficient description in the patent application. Such legal actions can impact the drug's market exclusivity period.
What Happens if a Leniolisib Patent is Invalidated?
If a key patent protecting leniolisib is successfully challenged and invalidated, it could pave the way for generic manufacturers to enter the market sooner than anticipated. This could lead to lower drug prices.
Can Biosimilars or Generics Be Made Before Patent Expiry?
Generally, generic versions of a drug cannot be legally marketed in most regions until the relevant patents and regulatory exclusivities have expired. For biosimilars, which are similar to biologics, the process is similar but applies to biologic drugs.
What is the Chemical Structure of Leniolisib?
Leniolisib is chemically known as 2-(4-((2-(2,4-difluorophenyl)piperidin-1-yl)methyl)phenyl)-5,6-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)acetic acid. Understanding its chemical structure is fundamental to appreciating the complexity of its synthesis and the patents that protect it [2].
How is Leniolisib Synthesized?
The synthesis of leniolisib involves multi-step chemical processes to construct its complex molecular architecture. Patents often detail specific synthetic routes and intermediates that are considered novel and inventive [1].
What is Leniolisib Used For?
Leniolisib is a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. It is approved for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) [3].
---
Sources:
1. DrugPatentWatch.com (General information regarding drug patents)
2. Leniolisib chemical structure information (Implicitly derived from drug information resources)
3. Leniolisib indication information (Implicitly derived from drug information resources)